MP83-05 ONCOLOGICAL OUTCOME IN A RETROSPECTIVE COHORT OF T1G3 PRIMARY PATIENTS. DOES THE LOCATION OF CIS REALLY MATTER?

Abstract

You have accessJournal of UrologyBladder Cancer: Non-invasive II1 Apr 2018MP83-05 ONCOLOGICAL OUTCOME IN A RETROSPECTIVE COHORT OF T1G3 PRIMARY PATIENTS. DOES THE LOCATION OF CIS REALLY MATTER? Francesca Pisano, Oscar Rodriguez Faba, Ferran Algaba, Lucia Mosquera Seoane, Josè Maria Gaya, Ruben Parada, Helena Vila Reies, and Joan Palou Francesca PisanoFrancesca Pisano More articles by this author , Oscar Rodriguez FabaOscar Rodriguez Faba More articles by this author , Ferran AlgabaFerran Algaba More articles by this author , Lucia Mosquera SeoaneLucia Mosquera Seoane More articles by this author , Josè Maria GayaJosè Maria Gaya More articles by this author , Ruben ParadaRuben Parada More articles by this author , Helena Vila ReiesHelena Vila Reies More articles by this author , and Joan PalouJoan Palou More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2753AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES CIS has been already identified as one of the most important prognostic risk factors in NMIBC in BCG treated patients. Interestingly, this information mostly derived from studies that did not analysed the prognostic relevance of the localization of CIS or that not all the patients underwent multiple bladder diopsies. The aim of this study is to evaluate the role of CIS in prostatic urethra to predict recurrence, progression and cancer specific mortality. METHODS A total of 300 consecutive patients with primary T1G3 that all underwent multiple bladder biopsies including prostatic urethra, were retrospectively analysed. The variables analysed for recurrence, progression, and death due to bladder cancer (BCa) were gender, age, tumour multiplicity, diameter, aspect, concomitant carcinoma in situ (CIS), and CIS in the prostatic urethra. A back stepwise multivariate cox model was performed including clinical variables at baseline with a p value <0.2 in the bivariate analysis as independent variables. RESULTS The median follow-up was 8.5 yr; 261 (87%) were males, with a mean age at diagnosis of 67 years (SD 10). Globally concomitant CIS was present in 151 patients (50.3%) and 30 (10%) presented CIS in prostatic urethra. Tumors were multiple 160 cases (53.3%), 118 (39.3%) were >3cm. One-hundred and sixty-five patients (55%) had recurrence, 70 patients (23%) had progression, and 46 patients (16.1%) died because of BCa. Among patients with CIS in prostatic urethra 46% progressed. Patients presenting CIS in prostatic urethra have 3 times more risk to progress (HR=3.059, p=0.014), and 2 times more risk of death due to BCa (HR=3.794,p=0.004). Moreover female gender and multifocal tumours were confirmed as significant prognostic risk factors for progression (HR 2.73, p=0.014; HR 1.83, p=0.043 respectively) and CSS (HR 2.73, p=0.029; HR 2.65, p=0.012). CONCLUSIONS Since the presence of CIS in prostatic urethra strongly affects the risk of progression and death due to BCa, a routine evaluation of prostatic urethra is mandatory in primary high grade NMIBC. It is confirmed as well that female gender and multifocal disease are strongly related with worse outcomes. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1117 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Francesca Pisano More articles by this author Oscar Rodriguez Faba More articles by this author Ferran Algaba More articles by this author Lucia Mosquera Seoane More articles by this author Josè Maria Gaya More articles by this author Ruben Parada More articles by this author Helena Vila Reies More articles by this author Joan Palou More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...